The subsidiary, called Xcede Technologies, will have patent-pending biomaterials technology for its "ready-to-use high-strength, fast-acting, combination hemostat/sealant," the company has announced in a release.
"The Xcede Patch requires minimal preparation time (less than 1 minute), is not dependent on patient coagulation and is highly effective on aggressive bleeding," Dynasil's release says.
The technology initially was invented by Dr.
Since 2011, Dynasil has further developed and refined the technology within its subsidiary, DBM of
Xcede has signed a license agreement with
Xcede Technologies has financing of up to
"Our new subsidiary will allow for a singular focus on development of the tissue sealant technology in order to bring the Xcede Patch to market," said
Xcede will be separately funded, relieving Dynasil of the need to fund development going forward, Sulick said. He saidXcede has "tremendous upside potential" and could revolutionize the
"This is the first spin out of technology developed internally at Dynasil," Sulick said. "We are hopeful that we can employ this model in the future as other technology we are working on both within DBM and RMD, our large research organization, reach maturity."
(c)2013 the Post-Bulletin
Visit the Post-Bulletin at www.postbulletin.com
Distributed by MCT Information Services